Neural respiratory drive as a physiological biomarker to monitor change during acute exacerbations of COPD

Patrick B Murphy,¹ Atul Kumar,² Charles Reilly,¹ Caroline Jolley,¹ Stephan Waltersbacher,² Fiammetta Fedele,³ Nicholas S Hopkinson,⁴ William D-C Man,⁴ Michael I Polkey,⁴ John Moxham,¹ Nicholas Hart⁵

► Additional data are published online only. To view these files please visit the journal online (<http://thorax.bmj.com>).

¹Department of Asthma, Allergy and Respiratory Science, Division of Asthma, Allergy and Lung Biology, King's College London, London, UK

²School of Medicine, King's College London, London, UK

³Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London, UK

⁴National Heart and Lung Institute, Respiratory Biomedical Research Unit, Royal Brompton Hospital and Imperial College London, London, UK

⁵Guy's and St Thomas' NHS Foundation Trust and King's College London, National Institute of Health Research Comprehensive Biomedical Research Centre, London UK

Correspondence to

Dr Patrick B Murphy, Lane Fox Respiratory Unit, St Thomas' Hospital, Westminster Bridge Road, London SE1 7EH, UK; patrick.b.murphy@kcl.ac.uk

Received 23 November 2010

Accepted 24 March 2011

Published Online First

19 May 2011

ABSTRACT

Background Acute exacerbations of chronic obstructive pulmonary disease have a significant negative impact on both patients and healthcare systems. Currently, there are no physiological biomarkers that effectively monitor clinical change or predict respiratory readmission. Acute exacerbations impose a change in the respiratory muscle load-capacity-drive relationship. It was hypothesised that lack of a fall in neural respiratory drive would identify patients at risk of treatment failure and early hospital readmission.

Methods An observational study was performed at two UK teaching hospitals. Routine clinical physiological parameters and neural respiratory drive index (NRDI), calculated as the product of second intercostal space parasternal electromyography (EMG) activity normalised to the peak EMG activity during a maximum inspiratory sniff manoeuvre and respiratory rate, were recorded daily from admission to discharge.

Results 30 acutely unwell patients of mean (SD) age 72 (10) years, forced expiratory volume in 1 s 0.60 (1.65) l, NRDI 455 (263) AU and median length of stay 6 days were studied. Changes in NRDI correlated with changes in Borg score ($r=+0.60$; $p<0.001$), discriminated between patients deemed to have clinically improved rather than deteriorated (mean difference 339 AU; 95% CI 234 to 444; $p<0.001$) and identified those patients readmitted within 14 days (mean difference 203 AU; 95% CI 39 to 366; $p=0.017$).

Conclusions NRDI is a feasible clinical physiological parameter in patients with an acute exacerbation of chronic obstructive pulmonary disease and can provide useful information on treatment response and risk of readmission.

INTRODUCTION

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are a major economic burden to healthcare systems.^{1 2} In addition, exacerbations have a significant impact on health-related quality of life (HRQL) with admission avoidance and reduced length of hospital admission becoming national targets.³ Recently, healthcare systems, including the National Health Service, have focused on providing enhanced community care to facilitate early discharge.^{4–6} Acute care organisations have incorporated early warning scores, integrating basic cardiorespiratory and other physiological variables into a composite score, as

Key messages

What is the key question?

► Can neural respiratory drive act as an advanced physiological biomarker for clinical change during acute exacerbations of COPD?

What is the bottom line?

► Neural respiratory drive, as measured non-invasively from parasternal electromyography, can accurately track clinical change during acute exacerbations of COPD and predict readmission to hospital.

Why read on?

► This paper reports the clinical usefulness of non-invasive advanced respiratory physiological monitoring in patients during an acute exacerbation of COPD.

predictors of clinical deterioration. However, the clinical usefulness of such scoring systems remains controversial.^{7–11} All these monitoring systems require accurate characterisation of disease severity and response to treatment to identify patients that are either deteriorating or only slowly improving to allocate patients to higher levels of clinical care. At present there are few physiological biomarkers available that have sufficient sensitivity and specificity to identify patients of AECOPD failing to respond to treatment.¹²

Neural respiratory drive (NRD) using diaphragm electromyography (EMG_{di}) reflects the balance between respiratory muscle load and capacity and has been shown to relate to disease severity in stable COPD.¹³ Despite its potential clinical usefulness, this technique has limited application in the acute setting as it requires the placement of an oesophageal electrode.^{13 14} Clinical interest has therefore been directed towards measuring the EMG of the parasternal intercostal muscles as these obligatory muscles of inspiration¹⁵ can be studied in a non-invasive manner.¹⁶ Parasternal EMG (EMG_{para}) signals, recorded from surface electrodes, have a direct relationship with respiratory muscle load¹⁷ and have been shown to respond to acute change.^{18 19}

The use of EMG_{para} to monitor treatment response in AECOPD has not previously been

reported. To be a useful clinical tool in the acute setting, the measurement must be reproducible in a stable setting and therefore one aim of this study was to establish the inter-occasion reproducibility of NRD in both healthy subjects and in patients with stable COPD. Furthermore, we hypothesised that changes in NRD would reflect clinical response to treatment during an AECOPD and a failure of NRD to fall would predict subsequent readmission to hospital.

METHODS

Subjects

The study protocol was approved by the local research ethics committees and all participants provided written informed consent. Two studies were performed to (1) validate the reproducibility of EMG_{para} in (a) healthy subjects and (b) patients with stable COPD and (2) investigate the ability of EMG_{para} as a physiological biomarker to monitor change in AECOPD. The methods and results of the reproducibility studies are given in the online supplement. The acute study recruited patients admitted with AECOPD via the emergency department. AECOPD was defined based on clinical features and basic investigations.⁶ Initial patient management was according to standard local guidelines with oral corticosteroids, antibiotics and a combination of metered dose inhalers and nebulised bronchodilators. Patients were identified by the COPD team and subsequently screened and recruited by the research team, with the first EMG_{para} measurement recorded within 24 hours of hospital arrival. Repeat EMG_{para} measurements and the clinical dataset were recorded daily until the patient was reported as stable and suitable for hospital discharge.

Baseline data

Demographic and anthropometric data were collected. Borg²⁰ and MRC dyspnoea scores^{21–22} were used to assess subjective breathlessness. HRQL data were obtained using the Chronic Respiratory Disease Questionnaire.²³ Spirometry was performed with a hand-held device (EasyOne Diagnostic Spirometer, ndd Medical Technologies, Switzerland) according to standard guidelines.^{24–25} Repeat measurements were taken during admission. The patient was seated and rested for at least 5 min; bronchodilator therapy was withheld for the previous 4 h. Heart rate (HR), oxygen saturations (S_pO_2) and respiratory rate (RR) were measured over 1 min. Clinical data (HR, S_pO_2 , RR, temperature (T), blood pressure (BP) and medical early warning score (MEWS)²⁶) and the supervising senior clinician's summary opinion on clinical course were recorded from the medical notes and observation charts. A patient was defined as a clinical 'deteriorator' or 'improver' based on the summary opinion of the senior attending respiratory physician (respiratory specialist registrar or consultant) and the requirement for increased treatment. The respiratory clinicians were blinded to the EMG_{para} measurement, which was analysed offline following patient discharge. EMG_{para} signals were acquired either in a chair or semirecumbent in bed. Oxygen therapy was only used when the S_pO_2 was $\leq 88\%$.

EMG_{para} measurement

The second intercostal space (ICS) was identified using surface bony landmarks and the skin was prepared prior to placement of electrodes. EMG_{para} signal acquisition and processing was analogous to the method described previously for EMG_{di} .¹³ Details are provided in the online supplement. The resting signal was normalised to the maximum value obtained from

a reproducible maximum sniff manoeuvre to produce the $EMG_{para\%max}$. To reflect changes in respiratory pattern, the product of $EMG_{para\%max}$ and RR was calculated to produce the neural respiratory drive index (NRDI; arbitrary units (AU)). Nasal cannulae connected to a differential pressure transducer (Validyne DP45, Validyne, Northridge, California, USA) identified inspiratory and expiratory phases of breathing.

Data analysis and statistics

Reproducibility was assessed using coefficient of variability and Bland–Altman analysis.²⁷ Relationships between EMG_{para} , $EMG_{para\%max}$ and NRDI and lung function parameters and HRQL data were analysed using regression analysis. Data were analysed using independent or paired t test where appropriate. Data that were not normally distributed, as defined by the Kolmogorov–Smirnov test, were transformed and then analysed as parametric data or, if the logarithm of the data remained non-normal, a non-parametric equivalent was used. Data analysis was conducted using SPSS software. All data are presented as mean $\pm$ SD unless otherwise stated, with $p < 0.05$ considered as statistically significant.

RESULTS

Reproducibility of EMG_{para}

EMG_{para} data are reported as root mean squared (RMS; μV). A representative trace of a patient with stable COPD during the sniff manoeuvres is shown in figure 1. Reproducibility of EMG_{para} was confirmed in 10 healthy volunteers and 10 patients with stable COPD. Further details can be found in the online supplement.

Change in EMG_{para} in patients with AECOPD

Thirty patients were recruited with a mean age of 72 ± 10 years (47% male). On admission, the median MRC dyspnoea score was 5 (2–5). The median previous admission frequency and length of stay was 3 (0–13) and 6 days (2–34), respectively. Baseline data are provided in table 1 and full details can be found in the online supplement (table E1). Three patients received non-invasive ventilation with all cases initiated in the first 4 h of admission in the emergency department. Nine patients were discharged with home oxygen, all of whom were previously prescribed long-term oxygen therapy.

Twenty-four patients had recordings on two occasions, five patients had recordings on three occasions and one patient had recordings on four occasions, producing 37 data pairs. Δ Borg score had a significant relationship with ΔEMG_{para} ($r = +0.50$; $p = 0.001$), $\Delta EMG_{para\%max}$ ($r = +0.57$; $p < 0.001$) and Δ NRDI ($r = +0.60$; $p < 0.001$) as shown in figure 2 and ΔFEV_1 ($r = -0.58$; $p = 0.002$). No relationship was observed with ΔS_pO_2 ($p = 0.16$) or ΔRR ($p = 0.08$).

Significant differences were observed in mean change between 'improvers' and 'deteriorators' in all three EMG_{para} indices. However, there were no significant between-group differences in changes in RR, HR, S_pO_2 or forced expiratory volume in 1 s (FEV_1) (table 2). A significant ($p = 0.02$) but clinically small ($+0.5$) difference was observed in MEWS between 'improvers' and 'deteriorators'. Patients who improved had a statistically significant reduction in dyspnoea (Δ Borg -1.5 ; 95% CI -0.7 to -2.3), RR (ΔRR -1.8 bpm; 95% CI -0.2 to -3.3) and an increase in FVC (ΔFVC 0.22 l; 95% CI 0.05 to 0.40), with no statistically significant differences demonstrable in physiological variables in the 'deteriorators'. Further data on daily changes in NRD can be found in the online supplement.

Receiver operating characteristics (ROC) plots (figure 3A) with change cut-offs $> +6.6$ for $EMG_{para\%max}$ and $> +160$ AU

Figure 1 Representative trace of raw data during maximum sniff manoeuvre in a patient with stable chronic obstructive pulmonary disease. Pnp, nasal pressure derived from nasal cannulae; EMG_{para}, parasternal electromyogram activity; RMS_{para}, root mean squared analysis of EMG_{para}.

for NRDI had sensitivities of 83% (95% CI 54% to 100%) and 100% (95% CI 100% to 100%) and specificities of 96% (95% CI 88% to 100%) and 100% (95% CI 100% to 100%) for both EMG_{para}%max and NRDI, respectively. ROC plots of the standard clinical variables either did not statistically differ from the null hypothesis or could not produce a cut-off providing sensitivity >80% without reducing specificity to <90% (figure 3B).

Change in EMG_{para} between admission and discharge to predict readmission

A significant difference in Δ EMG_{para}%max and Δ NRDI between admission (first measurement within 24 h of admission) and discharge (final measurement within 24 h of clinical stability) was demonstrated between patients readmitted within 14 days as a consequence of a respiratory deterioration and those who remained at home. However, Δ MEWS, Δ FEV₁ and number of previous admissions did not differ between patients who were and were not readmitted (table 3).

ROC plots (figure 4A) were calculated with cut-offs of a change in EMG_{para}%max >0% and NRDI >50 AU during admission, producing sensitivities of 67% (95% CI 36% to 97%) and 67% (95% CI 36% to 97%) and specificities of 62% (95% CI 41% to 83%) and 71% (95% CI 52% to 91%) for EMG_{para}%max and NRDI, respectively. None of the ROC plots for routine

clinical variables differed significantly from the null hypothesis (figure 4B).

DISCUSSION

This study has shown that second ICS parasternal NRDI, calculated as a product of EMG_{para} and RR normalised for maximum EMG_{para}, is a reproducible physiological biomarker in patients with stable COPD and has greater sensitivity and specificity than standard clinical physiological parameters to identify patients with AECOPD failing to respond to treatment. Furthermore, the failure of NRDI to fall during AECOPD requiring hospitalisation identifies patients who are more likely to be readmitted with a further respiratory deterioration.

Table 1 Standard clinical parameters and indices of neural respiratory drive on admission

	Emergency department	Baseline measurements
MEWS	3 (0–7)	2 (0–4)
FEV ₁ (l)	—	0.60±1.65
FVC (l)	—	1.53±0.82
PaO ₂ (kPa)	10.0±3.5	—
PaCO ₂ (kPa)	6.3±1.4	—
EMG _{para} %max (%)	—	20.3±9.9
NRDI (AU)	—	455±263

Data presented as median (range) and mean±SD.

EMG_{para}%max, EMG_{para} during tidal breathing normalised for maximum EMG_{para} produced during a sniff manoeuvre; FEV₁, forced expiratory volume in 1 s; MEWS, medical early warning score; NRDI, neural respiratory drive index (RR × EMG_{para}%max); PaCO₂, arterial partial pressure of carbon dioxide; PaO₂, arterial partial pressure of oxygen; RR, respiratory rate.

Figure 2 Data from 37 pairs of readings generated from consecutive recordings of physiological variables in 30 patients. Open circles represent 'improvers' and closed circles 'deteriorators'. Comparison of change in Borg score with change in (A) EMG_{para} (r=0.50; p=0.001), (B) EMG_{para}%max (r=0.57; p<0.001), (C) NRDI (r=0.60; p<0.001), (D) FEV₁* (r=−0.58; p=0.002). EMG_{para}, parasternal electromyogram activity; EMG_{para}%max, EMG_{para} during tidal breathing normalised for maximum EMG_{para} produced during a sniff manoeuvre; NRDI, neural respiratory drive index (EMG_{para}%max × RR). *Data from 26 pairs of data.

Table 2 Difference between consecutive recordings of measured physiological variables in 30 patients from day of baseline measurement to repeat reading

	Δ MEWS*	Δ RR	Δ S _p O ₂	Δ FEV ₁ †	Δ EMG _{para}	Δ EMG _{para} %max	Δ NRDI
'Deteriorators'	0.50 (0–1)	4.5±6.0	1.2±2.4	0.03±0.18	7.8±4.9	6.2±4.3	226±58
'Improvers'	0 (–2–1)	–1.8±3.8	0.9±2.7	0.06±0.14	–1.7±5.5	–3.5±8.1	–113±221
Mean difference (95% CI)		6.3 (–0.1 to 12.6)	–0.6 (–2.0 to 3.1)	0.03 (–0.42 to 0.36)	9.6 (4.4 to 14.8)	9.6 (4.5 to 14.8)	339 (234 to 444)
p Value	0.02	0.05	0.6	0.7	0.003	0.001	<0.001

Data presented as mean±SD or *median (range).

†Seven patients were unable to perform spirometry on one or more occasions so analysis of FEV₁ was performed on 'improvers' (n=20) and 'deteriorators' (n=3).

EMG_{para}%max, EMG_{para} during tidal breathing normalised for maximum EMG_{para} produced during a sniff manoeuvre; RR, respiratory rate; NRDI, neural respiratory drive index (RR × EMG_{para}%max); EMG_{para}, parasternal electromyogram activity; FEV₁, forced expiratory volume in 1 s; MEWS, medical early warning score.

Critique of the method

Patient selection

The patients with AECOPD recruited were not consecutive admissions and therefore subject to selection bias. Despite this limitation, the demographics and severity of patients were similar to previously reported data.²⁸ Furthermore, the goal of this study was to provide pilot data to demonstrate the feasibility and clinical usefulness of using non-invasive EMG monitoring as a physiological biomarker in the acute setting.

Surface EMG_{para} measurement

Although the issues of surface EMG recording are well described,²⁹ we acknowledge that contamination from other chest wall muscles cannot be excluded. However, we carefully observed patient and electrode position during data acquisition to maximise the contribution of second ICS parasternal muscle to the

inspiratory EMG_{para} signal and minimising the non-respiratory muscle activity of other muscles. Needle electrode technique could be used to isolate parasternal muscle activity^{30–31} but, similar to oesophageal measurement of diaphragm electrical activity, this invasive technique is not suitable for the acute setting.

Validity and reproducibility of EMG_{para}

EMG_{para}, as a measure of NRD, was shown to have satisfactory inter-occasion reproducibility in both healthy subjects and patients with stable COPD. Although the degree of variability with EMG_{para} in patients with COPD was greater in this study than that shown previously by our own group using EMG_{di}¹³ and EMG_{para} in patients with cystic fibrosis,³² the inter-occasion correlation for both healthy subjects and stable COPD was >0.80, which is a level that has previously been used to indicate acceptable inter-test agreement for surface electromyography.¹⁷

Definition of clinical change

The lack of an objective measure to monitor clinical progress in the acute setting to allow comparative changes with EMG_{para} is an obvious limitation of this study. All patients met an event-based criterion for a severe exacerbation of COPD requiring hospital admission.^{33–34} It is acknowledged that there is no 'gold standard' to predict or measure acute clinical progress in AECOPD,³⁴ and therefore we compared EMG_{para} with standard clinical parameters and the summary opinion of the supervising senior physician. While this is a broad definition, it is widely used in both research and clinical practice and is the benchmark by which other novel influential assessment tools have been judged.³⁵ Despite the limitations inherent in this choice of outcome, it allows the data to be easily interpreted. Clinical gestalt is the interpretation and analysis by the physician of the patient's report of their clinical state as well as the findings from the physical examination incorporating standard physiological variables and clinical parameters, which are subsequently processed as part of a learnt complex clinical algorithm to determine the clinical state of the patient and the response to treatment. In order to have measured the performance of this novel technique against a more definable objective marker, the study population may have to be limited to those patients in respiratory failure. However, this would have limited the applicability of the study and would have been difficult to demonstrate that measures of NRD added to already established and widely available techniques to measure clinical progress in this group.

Significance of findings

Parasternal muscle activity

Chest wall respiratory muscles have increased importance in patients with advanced COPD as progressive hyperinflation

Figure 3 Receiver operating characteristic (ROC) plot of change in (A) EMG_{para}%max and NRDI and (B) RR, MEWS, and FEV₁ for detection of clinical deterioration. EMG_{para}%max, EMG_{para} during tidal breathing normalised for maximum EMG_{para} produced during a sniff manoeuvre; FEV₁, forced expiratory volume in 1 s; NRDI, neural respiratory drive index; RR, respiratory rate; MEWS, medical early warning score.

Table 3 Difference between admission and discharge of measured physiological variables in 30 patients either readmitted (n=9) or not readmitted (n=21) within 14 days of hospital discharge

	Δ MEWS*	Δ FEV ₁ †	Previous admissions*	Δ EMG _{para} %max	Δ NRDI
Readmitted	0 (–1–2)	0.09±0.15	4 (0–14)	1.98±4.36	76±134
Not readmitted	0 (–3–2)	0.08±0.10	3 (0–10)	–4.05±10.30	–127±305
Mean difference (95% CI)		0.1 (0.14 to 0.11)		6.03 (11.5 to 0.54)	203 (39 to 366)
p Value	0.5	0.8	0.1	0.03	0.02

Data presented as mean±SD or *median (range).

†Seven patients were unable to perform spirometry on two occasions so analysis of FEV₁ was performed on readmitted (n=6) and not readmitted (n=17).

EMG_{para}%max, EMG_{para} during tidal breathing normalised for maximum EMG_{para} produced during a sniff manoeuvre; EMG_{para}, parasternal electromyogram activity; FEV₁, forced expiratory volume in 1 s; MEWS, medical early warning score; NRDI, neural respiratory drive index (respiratory rate × EMG_{para}%max).

impacts adversely on diaphragm positioning and efficiency,^{36–37} which results in a compensatory increase in chest wall and accessory respiratory muscle activity.^{38–39} In particular, the uppermost parasternal intercostal muscles have been shown to be important inspiratory muscles.^{40–42} Furthermore, these parasternals have minimal post-inspiratory activity⁴³ with the second ICS parasternal muscle demonstrating similar activity to the diaphragm.³⁰ However, during increasing hyperinflation, as observed during an AECOPD, the resting length of the parasternals is less affected than the diaphragm, such that the parasternals make a greater contribution to inspiratory pressure generation.⁴⁴ This increase in parasternal activity is also associated with higher levels of dyspnoea.⁴⁵ These data provide the scientific rationale to develop EMG_{para} as a physiological biomarker to track changes in clinical state in patients with

AECOPD. Patients failing to responding to therapy have persistent hyperinflation with sustained elevation in EMG_{para} activity compared with those responding to therapy and associated respiratory muscle unloading who have a decline in EMG_{para} activity as the lung volumes and diaphragm and parasternal activity return to baseline. Finally, NRD was expressed as a product of EMG_{para} and RR normalised for maximum EMG_{para} to produce NRDI, which incorporates the peak RMS inspiratory parasternal muscle activity per unit time as a ratio of maximum NRD, similar to pressure time index, which has been extensively used in previous studies as a dynamic measure of respiratory muscle fatigue.^{46–47}

Dyspnoea

Dyspnoea provides a significant symptom burden in COPD. An objective method of assessing the severity of breathlessness has previously been lacking, with clinicians using subjective assessment tools. Physiological indicators of disease severity in COPD, such as FEV₁, are acknowledged to be poorly predictive of dyspnoea.⁴⁸ In contrast, changes in NRD have been shown to explain variance in exercise-induced dyspnoea.⁴⁹ In the current study we observed a similar relationship between change in Borg score and change in EMG_{para}. Furthermore, as the initial measurements were recorded following commencement of emergency therapy, in some patients there were relatively small changes in second ICS parasternal muscle electrical activity and breathlessness, indicating that that this technique is sensitive enough to monitor relatively modest changes even after treatment initiation. These data therefore support the use of non-invasive second ICS parasternal EMG as a physiological biomarker of NRD that reflects perception of dyspnoea severity during AECOPD. Furthermore, as FEV₁ has a weak relationship with dyspnoea, there is potential for EMG_{para} to be applied to patients in the stable state to monitor progression of disease and detect exacerbation onset, although more work is required to fully elucidate this relationship.

Monitoring response to treatment

NRD was shown to monitor response to treatment in patients admitted with AECOPD when calculated as EMG_{para}%max and NRDI. The reproducibility data indicate that the cut-off chosen for maximum sensitivity and specificity of detection for clinical change (EMG_{para}%max >6.6%) represents a genuine and detectable change in NRD as it is above the 95% upper limit of agreement on the Bland–Altman plot. In this population of patients with AECOPD this would have correctly tracked deterioration in five out of six occasions. This high sensitivity and specificity was further improved with the addition of respiratory rate to produce the NRDI, which correctly identified all episodes of deterioration in this sample set. This

Figure 4 Receiver operating characteristic (ROC) plot of change in (A) EMG_{para}%max and NRDI and (B) RR, change in MEWS and number of previous admissions for hospital readmission at 14 days. EMG_{para}%max, EMG_{para} during tidal breathing normalised for maximum EMG_{para} produced during a sniff manoeuvre; NRDI, neural respiratory drive index; RR, respiratory rate; MEWS, medical early warning score.

demonstrates the potential clinical utility of the test with the integrated physiological signal accurately reflecting the summary opinion of the senior attending respiratory physician in a way unable to be replicated by any of the standard clinical variables assessed.

Readmission

In addition to the ability to track changes in NRD during AECOPD using this technique, we have also shown that failure of NRDI to fall in response to therapy identifies those patients who were likely to be readmitted within 14 days of discharge with further respiratory deterioration. At present there are no clinically useful biomarkers that can predict readmission in these patients.⁵⁰ Previous data in COPD patients with severe disease, as indicated by an FEV₁ <1 l at discharge or more than two previous admissions in the preceding 12 months, reported that these patients were more likely to be readmitted following an exacerbation of COPD.⁵¹ The specificity of these particular predictors in the current cohort of patients was poor at <0.5 and therefore these are not clinically useful. Failure of NRDI to fall in response to treatment provides an easy to apply novel physiological biomarker to predict readmission in high-risk patients. Data from the ECLIPSE study have suggested that the 'frequent exacerbator' is a distinct phenotype in COPD.⁵² The measurement of NRDI in this context is not simply acting as a measure of disease severity or to identify the frequent exacerbator phenotype because, if our analysis was limited to those patients with two or more previous admissions (n=22), the sensitivity and specificity to predict readmission at 14 days remained similar to the whole cohort at 63% and 64%, respectively. The ability of this physiological tool to maintain its sensitivity and specificity in the higher risk group of patients increases the clinical utility, with the ability to further risk stratify the most high-risk patients. With the increasing role of early discharge and COPD outreach schemes to support patients in the community,^{3,4} this technique could facilitate clinical selection to identify patients who require greater community support or further hospital treatment prior to discharge. This approach has increasing importance as the rising incidence of failed hospital discharge has been highlighted by the UK government as an area for improved performance with potential financial penalties for hospitals.⁵ Although these observational data have shown that measures of NRDI can identify treatment failure and readmission in patients with AECOPD, further validation of the technique is required with prospective interventional trials. These could focus on the ability to identify treatment failure to allow patients to be discharged with standard or supportive care packages with the aim of reducing readmissions and the serious sequelae of repeated exacerbations.

CONCLUSION

NRD, measured from second ICS parasternal EMG, is an objective physiological biomarker which is both reliable and reproducible in healthy subjects and patients with stable COPD. The technique is well tolerated and feasible in the acute care setting. NRDI, in contrast to other standard clinical parameters, is able to provide an objective marker of dyspnoea, track the clinical state of a patient during an AECOPD and predict readmission at 14 days.

Funding The work included within this manuscript was supported with grants from Guy's and St Thomas' Innovation Fund for Technology Transfer and NHS Innovations London. The authors acknowledge support from the Department of Health via the National Institute of Health Research (NIHR) Comprehensive Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with

King's College London and King's College Hospital NHS Foundation Trust. MIP's salary is part funded by the NIHR Respiratory Biomedical Research Unit of the Royal Brompton Hospital and Imperial College.

Competing interests None.

Ethics approval This study was conducted with the approval of the King's College Hospital REC.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Dahl R, Lofdahl CG. The economic impact of COPD in North America and Europe. Analysis of the Confronting COPD survey. Introduction. *Respir Med* 2003;**97**: (Suppl C):S1–2.
2. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;**23**:932–46.
3. National Clinical Strategy for Chronic Obstructive Pulmonary Disease, 2010. <http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Healthcare/Longtermconditions/COPD/index.htm> (accessed 2010).
4. British Thoracic Society Guideline Development Group. Intermediate care—Hospital-at-Home in chronic obstructive pulmonary disease: British Thoracic Society guideline. *Thorax* 2007;**62**:200–10.
5. Ram FS, Wedzicha JA, Wright J, et al. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. *BMJ* 2004;**329**:315.
6. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004;**59**(Suppl 1):1–232.
7. Heitz CR, Gaillard JP, Blumstein H, et al. Performance of the maximum modified early warning score to predict the need for higher care utilization among admitted emergency department patients. *J Hosp Med* 2010;**5**:E46–52.
8. McGaughey J, Alderdice F, Fowle R, et al. Outreach and Early Warning Systems (EWS) for the prevention of intensive care admission and death of critically ill adult patients on general hospital wards. *Cochrane Database Syst Rev* 2007;(3): CD005529.
9. Groarke JD, Gallagher J, Stack J, et al. Use of an admission early warning score to predict patient morbidity and mortality and treatment success. *Emerg Med J* 2008;**25**:803–6.
10. Mitchell IA, McKay H, Van Leuven C, et al. A prospective controlled trial of the effect of a multi-faceted intervention on early recognition and intervention in deteriorating hospital patients. *Resuscitation* 2010;**81**:658–66.
11. Hillman K, Chen J, Cretikos M, et al. Introduction of the medical emergency team (MET) system: a cluster-randomised controlled trial. *Lancet* 2005;**365**:2091–7.
12. Sin DD, Vestbo J. Biomarkers in chronic obstructive pulmonary disease. *Proc Am Thorac Soc* 2009;**6**:543–5.
13. Jolley CJ, Luo YM, Steier J, et al. Neural respiratory drive in healthy subjects and in COPD. *Eur Respir J* 2009;**33**:289–97.
14. Steier J, Jolley CJ, Seymour J, et al. Neural respiratory drive in obesity. *Thorax* 2009;**64**:719–25.
15. Hudson AL, Butler JE, Gandevia SC, et al. Interplay between the inspiratory and postural functions of the human parasternal intercostal muscles. *J Neurophysiol* 2010;**103**:1622–9.
16. Maarsingh EJ, van Eykern LA, Sprickelman AB, et al. Respiratory muscle activity measured with a noninvasive EMG technique: technical aspects and reproducibility. *J Appl Physiol* 2000;**88**:1955–61.
17. Duiverman ML, van Eykern LA, Vennik PW, et al. Reproducibility and responsiveness of a noninvasive EMG technique of the respiratory muscles in COPD patients and in healthy subjects. *J Appl Physiol* 2004;**96**:1723–9.
18. Maarsingh EJ, van Eykern LA, de Haan RJ, et al. Airflow limitation in asthmatic children assessed with a non-invasive EMG technique. *Respir Physiol Neurobiol* 2002;**133**:89–97.
19. Maarsingh EJ, Oud M, van Eykern LA, et al. Electromyographic monitoring of respiratory muscle activity in dyspneic infants and toddlers. *Respir Physiol Neurobiol* 2006;**150**:191–9.
20. Borg GA. Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;**14**:377–81.
21. Mahler DA, Rosiello RA, Harver A, et al. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. *Am Rev Respir Dis* 1987;**135**:1229–33.
22. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;**350**:1005–12.
23. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. *Thorax* 1987;**42**:773–8.
24. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;**16**:5–40.
25. Anon. Standardization of spirometry—1987 update. Statement of the American Thoracic Society. *Am Rev Respir Dis* 1987;**136**:1285–98.

26. **Subbe CP**, Kruger M, Rutherford P, *et al*. Validation of a modified Early Warning Score in medical admissions. *QJM* 2001;**94**:521–6.
27. **Bland JM**, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;**1**:307–10.
28. **Roberts CM**, Stone RA, Buckingham RJ, *et al*. Acidosis, non-invasive ventilation and mortality in hospitalised COPD exacerbations. *Thorax* 2011;**66**:43–8.
29. **Luo YM**, Moxham J, Polkey MI. Diaphragm electromyography using an oesophageal catheter: current concepts. *Clin Sci (Lond)* 2008;**115**:233–44.
30. **Gandevia SC**, Hudson AL, Gorman RB, *et al*. Spatial distribution of inspiratory drive to the parasternal intercostal muscles in humans. *J Physiol* 2006;**573**:263–75.
31. **Easton PA**, Hawes HG, Doig CJ, *et al*. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate. *Chest* 2010;**137**:558–65.
32. **Reilly CC**, Ward K, Jolley CJ, *et al*. Neural respiratory drive, pulmonary mechanics and breathlessness in patients with cystic fibrosis. *Thorax* 2011;**66**:240–6.
33. **Anthonisen NR**, Manfreda J, Warren CP, *et al*. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;**106**:196–204.
34. **Trappenburg JC**, van Deventer AC, Troosters T, *et al*. The impact of using different symptom-based exacerbation algorithms in patients with COPD. *Eur Respir J* 2011;**37**:1260–8.
35. **Leidy NK**, Wilcox TK, Jones PW, *et al*. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. *Am J Respir Crit Care Med* 2011;**183**:323–9.
36. **Sharp JT**, Goldberg NB, Druz WS, *et al*. Thoracoabdominal motion in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1977;**115**:47–56.
37. **Kyroussis D**, Polkey MI, Hammegard CH, *et al*. Respiratory muscle activity in patients with COPD walking to exhaustion with and without pressure support. *Eur Respir J* 2000;**15**:649–55.
38. **Martinez FJ**, Coughlin JI, Celli BR. Factors influencing ventilatory muscle recruitment in patients with chronic airflow obstruction. *Am Rev Respir Dis* 1990;**142**:276–82.
39. **Man WD**, Mustfa N, Nikolettou D, *et al*. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. *Thorax* 2004;**59**:471–6.
40. **Legrand A**, Wilson TA, Troyer AD. Mediolateral gradient of mechanical advantage in the canine parasternal intercostals. *J Appl Physiol* 1996;**80**:2097–101.
41. **De Troyer A**, Legrand A, Gayan-Ramirez G, *et al*. On the mechanism of the mediolateral gradient of parasternal activation. *J Appl Physiol* 1996;**80**:1490–4.
42. **De Troyer A**, Leduc D. Effect of diaphragmatic contraction on the action of the canine parasternal intercostals. *J Appl Physiol* 2006;**101**:169–75.
43. **Easton PA**, Hawes HG, Rothwell B, *et al*. Postinspiratory activity of the parasternal and external intercostal muscles in awake canines. *J Appl Physiol* 1999;**87**:1097–101.
44. **Martinez FJ**, Coughlin JI, Celli BR. Respiratory response to arm elevation in patients with chronic airflow obstruction. *Am Rev Respir Dis* 1991;**143**:476–80.
45. **Ward ME**, Eidelman D, Stubbings DG, *et al*. Respiratory sensation and pattern of respiratory muscle activation during diaphragm fatigue. *J Appl Physiol* 1988;**65**:2181–9.
46. **Bellemare F**, Grassino A. Effect of pressure and timing of contraction on human diaphragm fatigue. *J Appl Physiol* 1982;**53**:1190–5.
47. **Zocchi L**, Fitting JW, Majani U, *et al*. Effect of pressure and timing of contraction on human rib cage muscle fatigue. *Am Rev Respir Dis* 1993;**147**:857–64.
48. **Mahler DA**. The measurement of dyspnea during exercise in patients with lung disease. *Chest* 1992;**101**(5 Suppl):242S–7S.
49. **Marin JM**, Montes de Oca M, Rassulo J, *et al*. Ventilatory drive at rest and perception of exertional dyspnea in severe COPD. *Chest* 1999;**115**:1293–300.
50. **Cao Z**, Ong KC, Eng P, *et al*. Frequent hospital readmissions for acute exacerbations of COPD and their associated factors. *Respirology* 2006;**11**:188–95.
51. **Garcia-Aymerich J**, Farrero E, Felez MA, *et al*. Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. *Thorax* 2003;**58**:100–05.
52. **Hurst JR**, Vestbo J, Anzueto A, *et al*. Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010;**363**:1128–38.

Journal club

Gastric aspirate culture using the microscopic observation drug susceptibility (MODS) technique is superior to other methods for bacteriological confirmation of tuberculosis in children

Bacteriological evidence of tuberculosis in children is difficult to obtain and is not found in the majority of clinically suspected cases. In this study, which was conducted in Peru, gastric aspirates, nasopharyngeal aspirates and stool samples were taken from 218 children with clinically suspected tuberculosis and nasopharyngeal aspirates and stool samples were taken from 238 low-risk controls. These were examined by the microscopic observation drug susceptibility (MODS) technique broth culture, culture on Lowenstein–Jensen medium and PCR to identify the most effective diagnostic techniques.

10% of cases had at least one positive culture, of which 90.9% were detected by MODS culture compared with only 59.1% by Lowenstein–Jensen culture. Isolation by MODS culture was on average 15 days faster and MODS cultures were spoiled by contamination less often. All culture-positive cases had at least one positive result from a gastric aspirate sample. The yield from adding a second gastric aspirate sample to the first was 37% higher. Nasopharyngeal aspirate samples were positive in 54% of culture-positive cases and addition of a second nasopharyngeal aspirate specimen increased the yield by 50%. Stool cultures were positive in only 18% of culture-positive cases. Gastric aspirate PCR identified only half of clinically high-risk culture-positive cases, and 6.6% of controls had at least one positive PCR result. None of these controls developed evidence of clinical tuberculosis during 1 year of follow-up. The rate of false positive PCR results in any individual specimen was 2%.

These data suggest that the technique most likely to provide bacteriological confirmation of pediatric tuberculosis is MODS culture of gastric aspirates.

► **Oberhelman RA**, Soto-Castellares G, Gilman RH, *et al*. Diagnostic approaches for paediatric tuberculosis by use of different specimen types, culture methods, and PCR: a prospective case-control study. *Lancet Infect Dis* 2010;**10**:612–20.

Jane E Ho

Correspondence to Jane E Ho, Foundation Year 2, St Mary's Hospital, London, W2 1NY, UK; jane.ho@doctors.org.uk

Published Online First 22 October 2011

Thorax 2011;**66**:608. doi:10.1136/thx.2010.151902